RVMD
Ticker
Revolution Medicines, Inc.
RVMD · Healthcare · Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancersRevolution Medicines, Inc. (RVMD), in the Healthcare sector, has 54 disclosed filings on Paydirt over the trailing twelve months from 12 corporate insiders: 0 purchases and 54 sales, 1 filed past the deadline. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Oct 26 and filed Oct 28. The most active filer was Mark A Goldsmith with 11 filings. Data as of Nov 7 2026.
Add to watchlistFilings, ttm
54
0 buys · 54 sells · 1 late
Traders, ttm
12
12 insiders
Volume, ttmiDollar value disclosed in the window
$141.8M
estimated for Congress, as filed for insiders
Median delay
2d
execution to disclosure
Last traded
Oct 26
Filed Oct 28
ADViAverage daily dollar volume
$548.2M
market data
Share price · 12M
$191 (+205.0%)
Adjusted for splits and dividends.
Volume by month
Buys $60.0M
Sells $165.8M
Estimated for Congress, as filed for insiders · by filing month · past 24 months
Who filed · past 24 months
MGAll 13 filers
SPRecent filings
Anthony ManciniSALE
See Remarks
$432K2,310 sh × $186.99
Exec Oct 26
Filed Oct 28 · 6:00 PM ET Alan B. SandlerSALE Chief Development Officer $1.2M
6,008 sh across 4 lots
Exec Sep 29
Filed Oct 1 · 6:00 PM ET Jeff CisliniSALE SVP & General Counsel $159K
765 sh × $207.32
Exec Sep 25
Filed Sep 29 · 6:00 PM ET Anthony ManciniSALE See Remarks $743K
3,708 sh across 2 lots
Exec Sep 24
Filed Sep 28 · 6:00 PM ET Elizabeth M AndersonSALE Director $1.9M
10,043 sh across 4 lots
Exec Sep 22
Filed Sep 24 · 6:00 PM ET Anthony ManciniSALE See Remarks $347K
1,764 sh × $196.94
Exec Sep 18
Filed Sep 22 · 6:00 PM ET Anthony ManciniSALE See Remarks $348K
1,747 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:05 PM ET Stephen Michael KelseySALE See Remarks $1.1M
5,484 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:04 PM ET Margaret A HornSALE Chief Operating Officer $975K
4,891 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:03 PM ET Mark A GoldsmithSALE See Remarks $2.7M
13,775 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:02 PM ET Jeff CisliniSALE SVP & General Counsel $660K
3,314 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:01 PM ET Jack AndersSALE Chief Financial Officer $796K
3,992 sh × $199.30
Exec Sep 16
Filed Sep 18 · 6:00 PM ET Stephen Michael KelseySALE See Remarks $18.7M
92,531 sh across 8 lots
Exec Sep 11
Filed Sep 15 · 6:00 PM ET Anthony ManciniSALE See Remarks $3.1M
15,148 sh across 4 lots
Exec Sep 10
Filed Sep 14 · 6:03 PM ET Lorence H. KimSALE Director $3.5M
16,719 sh across 6 lots
Exec Sep 8
Filed Sep 10 · 5:52 PM ET Lorence H. KimSALE Director $11.3M
55,700 sh across 6 lots
Exec Aug 31
Filed Sep 2 · 4:30 PM ET Jeff CisliniSALE General Counsel $11.9M
56,894 sh across 6 lots
Exec Aug 21
Filed Aug 25 · 4:06 PM ET Mark A GoldsmithSALE See Remarks $17.7M
84,644 sh across 10 lots
Exec Aug 21
Filed Aug 25 · 4:06 PM ET Sushil PatelSALE Director $919K
4,880 sh across 6 lots
Exec Jun 29
Filed Jul 1 · 6:25 PM ET Jack AndersSALE Chief Financial Officer $3.3M
19,700 sh across 3 lots
Exec Jun 24
Filed Jun 26 · 5:30 PM ET Stephen Michael KelseySALE See Remarks $652K
4,175 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Jack AndersSALE Chief Financial Officer $425K
2,722 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Jeff CisliniSALE General Counsel $337K
2,157 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Mark A GoldsmithSALE See Remarks $1.6M
10,020 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Anthony ManciniSALE See Remarks $720K
4,615 sh × $156.12
Exec Jun 16
Filed Jun 18 · 5:30 PM ET